Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Stessman HA, et al. Among authors: janz s. Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27. Mol Cancer Ther. 2013. PMID: 23536725 Free PMC article.
Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.
Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Sun F, et al. Among authors: janz s. Haematologica. 2020 Mar;105(3):e111-e115. doi: 10.3324/haematol.2019.221127. Epub 2019 Jun 20. Haematologica. 2020. PMID: 31221780 Free PMC article. No abstract available.
Myeloma sleeper agent in myeloid disguise.
Dhakal B, Janz S. Dhakal B, et al. Among authors: janz s. Blood. 2019 Jul 4;134(1):3-4. doi: 10.1182/blood.2019001273. Blood. 2019. PMID: 31273002 Free article. No abstract available.
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Dhakal B, et al. Among authors: janz s. Cancer. 2020 Jun 15;126(12):2791-2801. doi: 10.1002/cncr.32831. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154922 Free article.
Trends in the use of therapeutic plasma exchange in multiple myeloma.
Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Dhakal B, et al. Among authors: janz s. J Clin Apher. 2020 Aug;35(4):307-315. doi: 10.1002/jca.21798. Epub 2020 Jun 9. J Clin Apher. 2020. PMID: 32516865
Autonomic nervous system control of multiple myeloma.
Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Cheng Y, et al. Among authors: janz s. Blood Rev. 2021 Mar;46:100741. doi: 10.1016/j.blre.2020.100741. Epub 2020 Aug 11. Blood Rev. 2021. PMID: 32807576 Free PMC article. Review.
276 results